Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bilastine Updosing in Chronic Spontaneous Urticaria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02213367
Recruitment Status : Completed
First Posted : August 11, 2014
Last Update Posted : August 26, 2016
Sponsor:
Information provided by (Responsible Party):
K. Weller, Charite University, Berlin, Germany

Brief Summary:
Chronic spontaneous urticaria (CSU), formerly also known as chronic idiopathic urticaria and chronic urticaria (CU), is one of the most frequent skin diseases. At any time, 0.5-1% of the population suffers from the disease. Although all age groups can be affected, the peak incidence is seen between 20 and 40 years of age. The duration of the disease is generally several years but is likely to be longer in more severe cases, cases with concurrent angioedema, in combination with physical urticaria or with a positive autologous serum skin test (autoreactivity). CSU has major detrimental effects on quality of life, with sleep deprivation and psychiatric comorbidity being frequent. It also has a large impact on society in terms of direct and indirect health care costs as well as reduced performance at work and in private life.

Condition or disease Intervention/treatment Phase
Chronic Urticaria Drug: Bilastine Drug: Bilastin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 3 Study, Exploratory, Disease Activity Controlled Dose Escalating Study to Assess the Efficacy, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Chronic Spontaneous Urticaria.
Study Start Date : July 2014
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hives

Arm Intervention/treatment
Active Comparator: 20 mg Bilastin
20mg Bilastine once daily
Drug: Bilastine
20mg (8 weeks)
Other Name: Bilaxten

Drug: Bilastine
40mg
Other Name: Bilaxten

Drug: Bilastin
80mg
Other Name: Bilaxten

Active Comparator: Bilastin 40mg
40 mg Bilastine once daily, intake of two tablets 20mg Bilastine
Drug: Bilastine
20mg (8 weeks)
Other Name: Bilaxten

Drug: Bilastine
40mg
Other Name: Bilaxten

Drug: Bilastin
80mg
Other Name: Bilaxten

Active Comparator: Bilastin 80mg
80 mg Bilastine once daily, intake of four tablets 20mg Bilastine
Drug: Bilastine
20mg (8 weeks)
Other Name: Bilaxten

Drug: Bilastine
40mg
Other Name: Bilaxten

Drug: Bilastin
80mg
Other Name: Bilaxten




Primary Outcome Measures :
  1. Effects of standard dose (20 mg) and higher than standard dose of bilastine (40 mg and 80 mg) on disease activity in patients with chronic spontaneous urticaria. [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. To assess the effects of standard dose (20 mg) and higher than standard dose of bilastine (40 mg and 80 mg) on quality of life impairment in patients with chronic spontaneous urticaria. [ Time Frame: 4 weeks ]

    To assess the safety of bilastine in doses of 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria patients by documentation of adverse events.

    To assess the effects of standard dose (20 mg) and higher than standard dose of bilastine (40 mg and 80 mg) on biomarkers of chronic spontaneous urticaria, such as substance P and D-Dimers




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female aged 18 years and older
  • History of active chronic spontaneous urticaria with or without associated angioedema for at least three days per week over the last 6 weeks prior to visit 1. - Urticaria symptoms must comprise wheals and itch
  • History of failed treatment with an antihistamine other than bilastine in standard (licensed) dose.
  • UAS7 of ≥14 during baseline
  • Informed consent signed and dated
  • Able to read, understand and willing to sign the informed consent form and abide with study procedures
  • Willing, committed and able to return for all clinic visits and complete all study-related procedures
  • In females of childbearing potential: negative pregnancy test; females willing to use highly effective contraception (Pearl-Index < 1) a woman will be considered not of childbearing potential if she is post-menopausal for > 2 years or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)
  • No participation in other clinical trials 4 weeks before and after participation in this study

Exclusion Criteria:

  • Chronic spontaneous urticaria patients with a known resistance to bilastine
  • Isolated presence or domination of inducible forms of urticaria or cholinergic urticaria (no chronic spontaneous urticaria)
  • History of adverse reactions to bilastine or known hypersensitivity to bilastine or its ingredients
  • Intake of oral corticosteroids or intravenously applied corticosteroids within 28 days prior to screening visit
  • Use of depot corticosteroids within 3 months prior to screening visit (inhaled corticosteroids are allowed)
  • Use of systemic immunosupressants/immunomodulators such as ciclosporin, dapsone, metotrexate, and comparable drugs within 28 days prior to screening visit.
  • Use of UV-therapy within 28 days prior to visit 1
  • Significant medical condition, in the opinion of the Investigator, rendering the patient immunocompromised or not suitable for a clinical trial
  • Significant concomitant illness, in the opinion of the Investigator, that would adversely affect the subject's participation or evaluation in this study
  • ECG alterations of repolarisation (QTc prolongations >450ms or increase of QTc >60ms as compared to the baseline assessment)
  • Blood pressure >180/100 mmHg and/or heart rate >100/min
  • Evidence of significant hepatic or renal disease (GOT and/or GPT >2 times above the upper reference value, serum creatinine 1.5 times above the upper reference value)
  • Subjects for whom there is concern, in the opinion of the Investigator, about compliance with the protocol procedures
  • The presence of a permanent gastrointestinal condition which may influence the oral therapy (chronic diarrhoea diseases, congenital malformations or surgical mutilations of gastrointestinal tract)
  • Presence of active cancer which requires chemotherapy or radiation therapy
  • Presence of alcohol abuse or drug addiction
  • Pregnancy or breast-feeding
  • Subjects who are inmates of psychiatric wards, prisons, or other state institutions. Existing or planned placement in an institution after ruling according to § 40 passage 1, number 4 AMG (Arzneimittelgesetz).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02213367


Locations
Layout table for location information
Germany
Dpt. of Dermatology and Allergy
Berlin, Germany, 10117
Sponsors and Collaborators
Charite University, Berlin, Germany
Investigators
Layout table for investigator information
Principal Investigator: Karsten Weller, MD Dpt. of Dermatology and Allergy , Charité

Layout table for additonal information
Responsible Party: K. Weller, PD, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier: NCT02213367     History of Changes
Other Study ID Numbers: BUCSU
First Posted: August 11, 2014    Key Record Dates
Last Update Posted: August 26, 2016
Last Verified: August 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Urticaria
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases